Tenaya Therapeutics, Inc. (TNYA) |
|
2.71 -0.16 (-5.57%)
|
09-27 16:00 |
|
Open: |
2.91 |
Pre. Close: |
2.87 |
|
High:
|
2.97 |
Low:
|
2.58 |
|
Volume:
|
858,483 |
Market Cap:
|
184(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:22:33 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 4.51 One year: 5.45 |
| Support: |
Support1: 2.55 Support2: 2.12 |
| Resistance: |
Resistance1: 3.86 Resistance2: 4.67 |
| Pivot: |
3.01 |
| Moving Average: |
MA(5): 2.79  MA(20): 3.19
MA(100): 5.24 MA(250): 3.81 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 20.2 %D(3): 19.3 |
| RSI: |
RSI(14): 31.9 |
| 52-week: |
High: 8.09 Low: 1.63 |
| Average Vol(K): |
3-Month: 327 (K) 10-Days: 585 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TNYA ] has closed above bottom band by 21.4%. Bollinger Bands are 30.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.97 - 2.99 |
2.99 - 3 |
|
Low:
|
2.55 - 2.56 |
2.56 - 2.57 |
|
Close:
|
2.69 - 2.71 |
2.71 - 2.73 |
|
Company Description |
|
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 27 Sep 2023
Does Tenaya Therapeutics Inc (TNYA) Have What it Takes to be in Your Portfolio Wednesday? - InvestorsObserver
Mon, 25 Sep 2023
Significant Block Trade of TNYA Shares Worth 135 Million - Best Stocks
Sat, 23 Sep 2023
Resumption of Trading Activity The Role of Trading Halts and ... - Best Stocks
Fri, 22 Sep 2023
Should You Buy Tenaya Therapeutics Inc (TNYA) Stock on Friday? - InvestorsObserver
Thu, 31 Aug 2023
Tenaya Therapeutics to Participate at the 21st Annual Morgan ... - GlobeNewswire
Wed, 09 Aug 2023
Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
68 (M) |
| Shares Float |
42 (M) |
|
% Held by Insiders
|
4.6 (%) |
|
% Held by Institutions
|
67.9 (%) |
|
Shares Short
|
2,920 (K) |
|
Shares Short P.Month
|
2,520 (K) |
Stock Financials |
|
EPS
|
-2.26 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.79 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-35.4 |
|
Return on Equity (ttm)
|
-62.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.86 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-107 (M) |
|
Levered Free Cash Flow
|
-67 (M) |
Stock Valuations |
|
PE Ratio
|
-1.2 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.96 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.73 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
